Search for a trial

A 52-week, randomized, double-blind, double-dummy, placebo- and active- controlled (Roflumilast, Daliresp® 500µg), parallel group, study to evaluate the efficacy and safety of two doses of CHF6001 DPI add-on to maintenance triple therapy in subjects with Chronic Obstructive Pulmonary Disease (COPD) and chronic bronchitis.

This study has been transitioned to CTIS with ID 2023-510174-13-00 check the CTIS register for the current data. The objective of the proposed study is to confirm the findings of the dose finding trial by, primarily, assessing the effect of two…

A 52-week, randomized, double-blind, placebo-controlled, parallel-group, study to evaluate the efficacy and safety of two doses of CHF6001 DPI add-on to maintenance triple therapy in subjects with Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis.

This study has been transitioned to CTIS with ID 2023-510175-60-00 check the CTIS register for the current data. The objective of the proposed study is to confirm the findings of the dose ranging trial by, primarily, assessing the effect of two…